Palisade Bio (PALI)

Executive Summary

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is designed for localized activation in the gastrointestinal tract, aiming to improve tolerability and convenience versus existing therapies for ulcerative colitis and Crohn's disease. The prodrug approach limits systemic exposure, potentially reducing side effects associated with other PDE4 inhibitors. Palisade's strategy targets the substantial unmet need in inflammatory bowel disease (IBD) and other inflammatory conditions, with a focus on differentiated pharmacology and patient compliance. The company has a strong intellectual property position around its prodrug platform and is progressing PALI-2108 through Phase 1 clinical trials.

Upcoming Catalysts (preview)

• Q3 2026PALI-2108 Phase 1 safety and PK data readout70% success
• H1 2027Initiation of Phase 2 trial in ulcerative colitis50% success
• TBDPotential partnership or licensing deal for PALI-210830% success